Tofidence™

Understanding Tofidence™ 

Tofidence™ (tocilizumab-bavi) is a biosimilar to Actemra® (tocilizumab), functioning as an interleukin-6 (IL-6) receptor antagonist. It is approved for the treatment of several inflammatory conditions, including moderately to severely active rheumatoid arthritis (RA) in adults, and active polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.

How Tofidence™ Works:

• IL-6 Receptor Blockade: Tocilizumab-bavi binds to IL-6 receptors, inhibiting the cytokine’s role in inflammation.

• Reduction of Inflammatory Activity: By blocking IL-6 signaling, Tofidence™ decreases inflammation, alleviating symptoms associated with RA, PJIA, and SJIA.

• Administration: Administered via intravenous infusion, with dosing frequency varying based on the specific condition.

FDA Approval:

• Tofidence™ received FDA approval on September 29, 2023, as a biosimilar to Actemra® for the treatment of RA, PJIA, and SJIA.

Speak with your healthcare provider to determine if Tofidence® is the right treatment option for you.